Sangamo BioSciences | SGMO - Ordinary Share Capital


Sangamo BioSciences reported $1.77M in Ordinary Share Capital for its fiscal quarter ending in June of 2023.





Ordinary Share Capital Change Date
Alaunos Therapeutics USD 2.21M 131K Sep/2025
Alnylam Pharmaceuticals USD 133.44M 1.07M Mar/2026
Alterity Therapeutics Limited AUD 10.88B 10.66B Dec/2025
Amgen USD 540M 1000K Mar/2026
Bayer EUR 982.42M 0 Dec/2025
BioCryst Pharmaceuticals USD 213.06M 2.54M Dec/2025
Biogen USD 146.7M 200K Sep/2025
BioMarin Pharmaceutical USD 193.27M 969K Mar/2026
Cipla INR 807.78M 17K Mar/2026
Clal Biotechnology ILS 1.61M 0 Dec/2022
Compugen USD 94.55M 1.02M Dec/2025
CSL USD 482.13M 93.87M Dec/2025
Gilead Sciences USD 1.24B 1000K Mar/2026
GlaxoSmithKline GBP 4.05B 20.6M Mar/2026
Grifols EUR 680.58M 846.11K Dec/2025
Ionis Pharmaceuticals USD 165.9M 3.93M Mar/2026
J&J USD 2.41B 1.74M Dec/2025
Karyopharm Therapeutics USD 18.31M 18.3M Dec/2025
Merck USD 2.47B 12.72M Dec/2025
Novartis USD 1.91B 60K Mar/2026
Omeros USD 611K 17K Dec/2023
Pfizer USD 5.7B 13M Mar/2026
Roche Holding CHF 795.62M 699.54K Dec/2025
Sanofi EUR 1.21B 8.25M Mar/2026
Sarepta Therapeutics USD 105.57M 607K Mar/2026
Tectonic Therapeutic USD 18.74M 25.03K Dec/2025
Ultragenyx Pharmaceutical USD 98.3M 1.7M Mar/2026
Vertex Pharmaceuticals USD 254.2M 200K Mar/2026